185 related articles for article (PubMed ID: 27522991)
41. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
42. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
43. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
44. Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
Shakado S; Iwata K; Tsuchiya N; Kunimoto H; Yotsumoto K; Fukunaga A; Kuno S; Tanaka T; Sakurai K; Iwashita H; Hirano G; Yokoyama K; Morihara D; Nishizawa S; Takeyama Y; Irie M; Sohda T; Kora S; Yoshimitsu K; Sakisaka S
Hepatogastroenterology; 2014 May; 61(131):557-62. PubMed ID: 26176035
[TBL] [Abstract][Full Text] [Related]
45. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
[TBL] [Abstract][Full Text] [Related]
47. [Successful treatment for advanced hepatocellular carcinoma by hepatic arterial infusion of CDDP powder as second-line chemotherapy].
Gen Y; Kimura H; Akitake R; Sakai A; Fukui A; Takao T; Ikezawa S; Masuda A; Takashima H; Funatsu E; Nakamura H; Okuyama Y; Arai M; Yagi N; Kutsumi H; Fujimoto S; Takeuchi Y
Gan To Kagaku Ryoho; 2006 Apr; 33(4):505-8. PubMed ID: 16612162
[TBL] [Abstract][Full Text] [Related]
48. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
49. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
50. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.
Kamimura K; Suda T; Yokoo T; Kamimura H; Kanefuji T; Tsuchiya A; Takamura M; Kawai H; Waguri N; Yamagiwa S; Terai S
BMC Cancer; 2017 May; 17(1):322. PubMed ID: 28490356
[TBL] [Abstract][Full Text] [Related]
51. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Kondo M; Morimoto M; Numata K; Nozaki A; Tanaka K
Jpn J Clin Oncol; 2011 Jan; 41(1):69-75. PubMed ID: 20688778
[TBL] [Abstract][Full Text] [Related]
52. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
53. [Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].
Xu Y; Wang PX; Cheng JW; Huang XW; Zhou J; Fan J; Yang XR
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):918-923. PubMed ID: 33256276
[No Abstract] [Full Text] [Related]
54. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
55. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma.
Suehiro T; Matsumata T; Itasaka H; Taketomi A; Yamamoto K; Sugimachi K
Surgery; 1995 Jun; 117(6):682-91. PubMed ID: 7539944
[TBL] [Abstract][Full Text] [Related]
56. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
57. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K
BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075
[TBL] [Abstract][Full Text] [Related]
58. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
59. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma.
Shibata J; Fujiyama S; Sato T; Kishimoto S; Fukushima S; Nakano M
Cancer; 1989 Oct; 64(8):1586-94. PubMed ID: 2477131
[TBL] [Abstract][Full Text] [Related]
60. The Early Decline of α-Fetoprotein and Des-γ-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients.
Yamamoto S; Onishi H; Takaki A; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Shiraha H; Okada H
Gastrointest Tumors; 2020 Jul; 7(3):83-92. PubMed ID: 32903927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
